PHA-680626

• CAT Number: I008735
• CAS Number: 398493-74-8
• Molecular Formula: C23H26N6O2S
• Molecular Weight: 450.56
• Purity: ≥95%
• Synonyms: PHA680626; PHA 680626; PHA-680626.;4-(4-methylpiperazin-1-yl)-N-(5-(2-(thiophen-2-yl)acetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)benzamide.
• Target: PLK1 inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 4-(4-methylpiperazin-1-yl)-N-[5-(2-thiophen-2-ylacetyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]benzamide
• InChI: InChI=1S/C23H26N6O2S/c1-27-8-10-28(11-9-27)17-6-4-16(5-7-17)23(31)24-22-19-14-29(15-20(19)25-26-22)21(30)13-18-3-2-12-32-18/h2-7,12H,8-11,13-15H2,1H3,(H2,24,25,26,31)
• InChIKey: BMCKWRUTJXVUFF-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC4=C3CN(C4)C(=O)CC5=CC=CS5

PHA-680626（Cat No.:I008735）is a selective, small-molecule inhibitor of the serine/threonine kinase PIM1 (proviral integration site for Moloney murine leukemia virus), which is involved in cell survival, proliferation, and tumorigenesis. PIM1 is overexpressed in several types of cancer and contributes to resistance to apoptosis and chemotherapy. By inhibiting PIM1, PHA-680626 has shown potential in preclinical studies for reducing cancer cell proliferation and enhancing the effects of other cancer treatments. It is being explored as a promising therapeutic option for targeting cancers with elevated PIM1 activity, particularly in hematologic malignancies and solid tumors.